Drugs / EDP239
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02173574 | Aug → Nov 2014 | hepatitis C virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01856426 | Jun 2013 → Nov 2014 | chronic hepatitis C virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-239 | “Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.” PMID 27503640 ↗ Sep 2016 |
| Action | Inhibit | “EDP-239 is a potent, selective inhibitor with potency at picomolar to nanomolar concentrations against HCV genotypes 1 through 6.” PMID 27503640 ↗ Sep 2016 |